“Brain Imaging in Tobacco Smokers During a Quit Attempt”
The proposed study will help fill gaps in existing research by determining if nicotine-dependent cigarette smokers show changes in I?7 nicotinic acetylcholine receptor (nAChR) availability when compared to matched historical controls using positron emission tomography (PET) imaging and the radioactive ligand [18F]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6 [18F]fluorodibenzo[b,d]thiophene 5,5-dioxide), an I?7 nAChR antagonist. The study will also explore whether I?7 nAChR availability influences clinically relevant measures of tobacco abstinence (e.g., withdrawal and craving, cognitive impairment), self-reported cigarettes per day, and time to relapse during an 8-day quit attempt during which smokers can receive escalating payments contingent upon providing objective evidence (breath CO and urinary cotinine) of smoking abstinence.
Drug - [F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)
Brain imaging of alpha-7 nicotinic acetylcholine receptors
Behavioral - Contingency Management
Incentive payments contingent upon provision of samples that meet criterion levels of exhaled carbon oxide and urinary cotinine at study visits
Brain Imaging of Nicotinic Acetylcholine Receptors in Tobacco Users and Nonusers